Graham Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Graham Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,596	Closed	-$601K	–	1344
2025 Q4	$601K	Sell	7,596 -9,567	-56%	-$720K	0.01%	561
2025 Q3	$1.12M	Sell	17,163 -3,772	-18%	-$184K	0.02%	350
2025 Q2	$827K	Buy	+20,935	New	+$685K	0.01%	641
2024 Q2	–	Sell	-30,541	Closed	-$1.32M	–	1187
2024 Q1	$1.32M	Buy	30,541 +18,016	+144%	+$859K	0.02%	342
2023 Q4	$634K	Sell	12,525 -1,963	-14%	-$94K	0.01%	519
2023 Q3	$657K	Buy	+14,488	New	+$598K	0.02%	486
2022 Q4	–	Sell	-53,717	Closed	-$2.38M	–	1169
2022 Q3	$2.38M	Sell	53,717 -7,296	-12%	-$307K	0.09%	178
2022 Q2	$2.26M	Buy	61,013 +40,913	+204%	+$1.54M	0.09%	175
2022 Q1	$744K	Buy	20,100 +13,296	+195%	+$435K	0.03%	415
2021 Q4	$207K	Buy	+6,804	New	+$214K	0.01%	457

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's IONS Position: Q1 2026 in Review

Graham Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 7,596 shares — an estimated $601K sold.

Graham Capital Management first reported a position in IONS in Q4 2021 and held it in 10 quarters. The position peaked at $2.38M in Q3 2022. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Graham Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 7,596 Ionis Pharmaceuticals shares in Q1 2026, an estimated $601K.
Graham Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Graham Capital Management's Ionis Pharmaceuticals position peaked at $2.38M in Q3 2022.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.